Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERTIL-01: A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma

NCT07651618 is registered in ClinicalTrials.gov with East Metropolitan Health Service, Australia as lead sponsor.

NCT NCT07651618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07651618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERTIL-01: A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma
Lead sponsor
East Metropolitan Health Service, Australia
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
April 30, 2032
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin cancer), melanoma metastatic